Antibody-Drug Conjugates in Triple Negative Breast Cancer
Clinical Breast Cancer · 2024-04 · 24 (3) · 163-174
DOI: 10.1016/j.clbc.2024.01.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Breast Cancer, 2024-04. Verfasst von Merve Keskinkilic und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Breast Neoplasms, Antineoplastic Agents, Immunoconjugates. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 96 Literaturangaben.
Abstract (Originalsprache)
Triple negative breast cancer (TNBC) accounts for 15%-20% of all breast cancer. It is a heterogeneous breast cancer subtype with a poor prognosis. Given these negative features, there is a need for new treatment options beyond conventional chemotherapy in both the early stage and palliative setting. Impressive results have been reported with antibody-drug conjugates (ADCs) that link a cytotoxic payload to a monoclonal antibody, such as sacituzumab govitecan and trastuzumab deruxtecan, in the metastatic stage. The focus of this review is to discuss completed and ongoing trials involving ADCs in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.
- Winship Cancer Institute, Emory University, Atlanta GA. Electronic address: rlsacks@emory.edu.
Zitieren
APA
Keskinkilic, M., & Sacks, R. (2024). Antibody-Drug Conjugates in Triple Negative Breast Cancer. Clinical Breast Cancer, 24(3), 163-174. https://doi.org/10.1016/j.clbc.2024.01.008
Vancouver
Keskinkilic M, Sacks R. Antibody-Drug Conjugates in Triple Negative Breast Cancer. Clinical Breast Cancer. 2024;24(3):163-174. doi:10.1016/j.clbc.2024.01.008
BibTeX
@article{Keskinkilic2024,
author = {Keskinkilic, Merve and Sacks, Ruth},
title = {Antibody-Drug Conjugates in Triple Negative Breast Cancer},
journal = {Clinical Breast Cancer},
year = {2024},
volume = {24},
number = {3},
pages = {163--174},
doi = {10.1016/j.clbc.2024.01.008}
}
EUVIMED